Angoorani Pooneh, Ejtahed Hanieh-Sadat, Ettehad Marvasti Fateme, Taghavi MinaSadat, Mohammadpour Ahranjani Behzad, Hasani-Ranjbar Shirin, Larijani Bagher
Obesity and Eating Habits Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Microbiota Research Group, Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Front Med (Lausanne). 2023 Jun 9;10:1141355. doi: 10.3389/fmed.2023.1141355. eCollection 2023.
Accumulating evidence has highlighted the critical role of the gut microbiota and its potential action as a regulator of metabolic disorders including insulin resistance, obesity, and systemic inflammation in polycystic ovarian syndrome (PCOS). Microbiota-modulating interventions, such as probiotics, prebiotics, and synbiotics, could be effective in PCOS management.
We conducted an overview of systematic reviews (SRs) and meta-analyses to summarize reviews regarding the effectiveness of probiotics/prebiotics/synbiotics on the management of PCOS through a systematic literature search in PubMed, Web of Science, and Scopus databases until September 2021.
Eight SRs and meta-analyses were included in this study. Our overview confirmed that probiotic supplementation had a potentially beneficial effect on some PCOS-related parameters including body mass index (BMI), fasting plasma glucose (FPG), and lipid profiles. Evidence shows that synbiotics in comparison with probiotics were less effective on these parameters. The methodological quality of SRs was assessed using the AMSTAR-2 assessment tool and was determined as high for four SRs, low for two SRs, and critically low for one SR. Due to limited evidence and high heterogeneity of the studies, it remains difficult to identify optimal probiotics strains, prebiotics types, length of duration, and doses.
Future clinical trials with higher quality are recommended to clarify the efficacy of probiotics/prebiotics/synbiotics on the management of PCOS and provide more accurate evidence.
越来越多的证据凸显了肠道微生物群的关键作用及其作为代谢紊乱调节因子的潜在作用，这些代谢紊乱包括多囊卵巢综合征（PCOS）中的胰岛素抵抗、肥胖和全身炎症。微生物群调节干预措施，如益生菌、益生元及合生元，可能对PCOS的管理有效。
我们进行了系统评价（SRs）和荟萃分析的概述，以通过在PubMed、科学网和Scopus数据库中进行系统文献检索，总结关于益生菌/益生元/合生元对PCOS管理有效性的综述，检索截至2021年9月。
本研究纳入了8项SRs和荟萃分析。我们的概述证实，补充益生菌对一些与PCOS相关的参数有潜在益处，包括体重指数（BMI）、空腹血糖（FPG）和血脂谱。有证据表明，与益生菌相比，合生元在这些参数上效果较差。使用AMSTAR-2评估工具评估SRs的方法学质量，确定4项SRs为高质量，2项SRs为低质量，1项SRs为极低质量。由于证据有限且研究异质性高，仍然难以确定最佳的益生菌菌株、益生元类型、持续时间和剂量。
建议未来开展更高质量的临床试验，以阐明益生菌/益生元/合生元对PCOS管理的疗效，并提供更准确的证据。
